Abbott’s Cholesterol Drug Deal with AstraZeneca
By Taskin Ahmed
PharmaDeals Review: Vol 2009 Issue 6 (Table of Contents)
Published: 17 Jun-2009
DOI: 10.3833/pdr.v2009i6.1123 ISSN: 1756-7874
Section: Distribution & Marketing
Fulltext:
Abstract
AstraZeneca is to co-promote Abbott’s Trilipix® (fenofibric acid) for the treatment of lipid disorders, which will increase the exposure of Trilipix in the cholesterol market...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login on the top right purple box.
Copyright: PharmaVentures Ltd
RSS